|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-1-13
|
|
pubmed:abstractText |
The conventional primary end point in trials of perioperative systemic therapy for muscle invasive bladder cancer is 5-year overall survival. We identified an association between disease-free survival at 2 to 3 years and 5-year overall survival.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1527-3792
|
|
pubmed:author |
pubmed-author:BastianPatrick JPJ,
pubmed-author:DinneyColin PCP,
pubmed-author:FicarraVincenzoV,
pubmed-author:FradetYvesY,
pubmed-author:FritscheHans-MartinHM,
pubmed-author:IzawaJonathan IJI,
pubmed-author:KarakiewiczPierre IPI,
pubmed-author:KassoufWassimW,
pubmed-author:KhanMyrna MMM,
pubmed-author:LernerSeth PSP,
pubmed-author:LotanYairY,
pubmed-author:NovaraGiacomoG,
pubmed-author:SagalowskyArthur IAI,
pubmed-author:SchoenbergMarkM,
pubmed-author:ShariatShahrokh FSF,
pubmed-author:SkinnerEilaE,
pubmed-author:SonpavdeGuruG,
pubmed-author:SvatekRobert SRS,
pubmed-author:TilkiDeryaD
|
|
pubmed:copyrightInfo |
Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
185
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
456-61
|
|
pubmed:meshHeading |
pubmed-meshheading:21167527-Adult,
pubmed-meshheading:21167527-Aged,
pubmed-meshheading:21167527-Aged, 80 and over,
pubmed-meshheading:21167527-Carcinoma, Transitional Cell,
pubmed-meshheading:21167527-Cohort Studies,
pubmed-meshheading:21167527-Confidence Intervals,
pubmed-meshheading:21167527-Cystectomy,
pubmed-meshheading:21167527-Disease-Free Survival,
pubmed-meshheading:21167527-Female,
pubmed-meshheading:21167527-Follow-Up Studies,
pubmed-meshheading:21167527-Humans,
pubmed-meshheading:21167527-Kaplan-Meier Estimate,
pubmed-meshheading:21167527-Male,
pubmed-meshheading:21167527-Middle Aged,
pubmed-meshheading:21167527-Neoplasm Invasiveness,
pubmed-meshheading:21167527-Neoplasm Recurrence, Local,
pubmed-meshheading:21167527-Neoplasm Staging,
pubmed-meshheading:21167527-Proportional Hazards Models,
pubmed-meshheading:21167527-Reproducibility of Results,
pubmed-meshheading:21167527-Retrospective Studies,
pubmed-meshheading:21167527-Risk Assessment,
pubmed-meshheading:21167527-Survival Analysis,
pubmed-meshheading:21167527-Treatment Outcome,
pubmed-meshheading:21167527-Urinary Bladder Neoplasms,
pubmed-meshheading:21167527-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer.
|
|
pubmed:affiliation |
Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA. gurus@bcm.edu
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study
|
